Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 306 Products   1129 Diseases   306 Products   4023 Trials   219432 News 


«12...1314151617181920212223...26722673»
  • ||||||||||  Real-world treatment patterns and survival outcomes of adjuvant therapies in stage III resected melanoma in France () -  Apr 20, 2026 - Abstract #EADO2026EADO_308;    
    Background Before the advent of neoadjuvant immunotherapy (IO) in macroscopic disease, guidelines on the management of stage III (sIII) resectable melanoma recommended surgery followed by adjuvant IO (nivolumab (NIVO), pembrolizumab (PEM)) or targeted BRAFMEK therapy (dabrafenib-trametinib (DT))...Among the 1,075 patients receiving a first therapy after recurrence (616 NIVO, 247 PEM, 212 DT), 785 (73.0%) received IO at recurrence
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    Real-world outcomes of palliative anti () -  Apr 20, 2026 - Abstract #EADO2026EADO_304;    
    Albumin, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were dichotomised using institutional limits. LIPI was defined as derived neutrophil-to-lymphocyte ratio (dNLR) >3 plus LDH > upper limit
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Melanoma with rhabdomyoblastic features  () -  Apr 20, 2026 - Abstract #EADO2026EADO_276;    
    The patient initiated pembrolizumab therapy in June 2024...Conclusions There is a lack of data describing the treatment of melanoma with rhabdomyoblastic features. Because of the aggressive nature of the disease, it is worth considering combining systemic therapy with radiotherapy in case of locallyadvanced tumours.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / BMS
    Melanoma in Palestine: First Real-World Outcomes from a National Retrospective Cohort () -  Apr 20, 2026 - Abstract #EADO2026EADO_275;    
    Because of the aggressive nature of the disease, it is worth considering combining systemic therapy with radiotherapy in case of locallyadvanced tumours. Systemic therapy was categorized as anti
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
    Is Nivolumab/Relatlimab a last-line option after failure of anti-PD1/anti-CTLA-4 inhibition? Early data from a retrospective comparison between available regimens () -  Apr 20, 2026 - Abstract #EADO2026EADO_264;    
    Providing patients with detailed information about possible serious side effects, some of which can be fatal, is and remains essential in everyday therapy. The treatment outcomes are presented in comparison with the recently published outcomes of pembrolizumab/lenvatinib and conventional chemotherapy (CC) [2]...PFS and OS curves of last line therapeutic options Grade ?3 treatment-related adverse events (TRAEs) were documented in 36.8% of nivolumab/relatlimab treated patients, leading to treatment discontinuation in 10.5% of cases ( Tab.1).Conclusions Nivolumab/relatlimab is a safe and efficient last-line therapy in real-world metastatic melanoma patients with prior progression on anti
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    Influence of the timing of adjuvant immunotherapy initiation on recurrence-free survival in melanoma () -  Apr 20, 2026 - Abstract #EADO2026EADO_262;    
    This was maintained in the multivariate analysis performed according to methods.Conclusions The timing of immunotherapy initiation may influence SLR, but the data in the literature are still contradictory. Further studies are needed to try to define the best timing of IT initiation in relation to surgery that leaves the patient disease-free.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / BMS
    Immune-Mediated Hepatitis in Cutaneous Malignancies: A Real-World Retrospective Study () -  Apr 20, 2026 - Abstract #EADO2026EADO_254;    
    Further studies are needed to try to define the best timing of IT initiation in relation to surgery that leaves the patient disease-free. Most IMH episodes were associated with melanoma (92%) and occurred in advanced or metastatic disease (72%), with pembrolizumab (44%) and ipilimumab
  • ||||||||||  Evaluation of coagulopathy in patients with advanced skin cancer during treatment with immune checkpoint inhibitors () -  Apr 20, 2026 - Abstract #EADO2026EADO_249;    
    We also present the case of a 67-year-old male patient who was diagnosed with advanced squamous cell skin cancer (T4N0M0) and treated with cemiplimab. This patient developed severe multi-organ failure, which turned out to be related to immune-mediated thrombotic thrombocytopenic purpura (case 5).Conclusions A multidisciplinary approach is essential in the diagnosis and management of adverse events in skin cancer patients receiving immune checkpoint inhibitor therapy, and is also crucial in deciding whether to continue immunotherapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date:  NePenThe: Pembrolizumab in High-risk Thyroid Cancer (clinicaltrials.gov) -  Apr 20, 2026   
    P2,  N=25, Recruiting, 
    Among available treatments, combination anti Trial completion date: Dec 2027 --> Nov 2026
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Journal:  BRCA2-dependent maturation of nascent strands during DNA replication. (Pubmed Central) -  Apr 19, 2026   
    Critically, this process is dependent on the tumor suppressors BRCA1 and BRCA2 and is associated with the BRCA2-dependent accumulation of RAD51 recombinase in chromatin. Our data identify nascent strand gaps that are induced by olaparib independently of replication fork reversal and/or PRIMPOL-mediated repriming and that are repaired by a BRCA2-dependent process that we propose is daughter-strand gap protection and/or repair occurring hundreds of kilobases behind DNA replication forks.
  • ||||||||||  Remicade (infliximab) / J&J, Yervoy (ipilimumab) / BMS
    Journal:  Caffeine as a Viscosity-Reducing Agent for High-Concentration mAb Formulations: Insights from Molecular Dynamics Simulations. (Pubmed Central) -  Apr 19, 2026   
    The conformational analysis based on K-means clustering suggested that, in the presence of caffeine, the conformations of both the Fab and Fc fragments became more rigid without a significant change in the overall mAb compactness. These findings provide molecular-level insights into the potential use of caffeine as a new viscosity-reducing agent for high-concentration mAb formulations.
  • ||||||||||  Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
    Journal:  Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance. (Pubmed Central) -  Apr 19, 2026   
    In samples collected after a ring vaccination campaign in Guinea, combined sGP and VSV-P-N positivity confirmed vaccination in 94.8% of persons with written and 90.8% of persons with verbal confirmation of vaccination history. Our findings show that sGP and VSV-P-N provide a reliable signature of ERVEBO vaccination and support improved Ebola surveillance.
  • ||||||||||  vildagliptin / Generic mfg., saxagliptin / Generic mfg., Januvia (sitagliptin) / Merck (MSD)
    Journal:  Assessing the therapeutic effects of DPP4 Inhibitors on TGF-?2-induced Lens Opacity. (Pubmed Central) -  Apr 19, 2026   
    These findings suggest that DPP4 inhibitors, particularly Vildagliptin, may offer a novel, non-invasive pharmacological approach to preventing PCO by targeting TGF-? signaling pathways.
  • ||||||||||  Preclinical, Journal:  Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro. (Pubmed Central) -  Apr 19, 2026   
    A482G conferred slight cross-resistance to bemnifosbuvir, while no cross-resistance was observed for remdesivir, galidesivir, or NITD008...Sofosbuvir RAS described for other orthoflaviviruses did not substantially affect drug susceptibility in reverse-engineered YFV 17D. This study demonstrates that YFV can develop resistance to sofosbuvir and uprifosbuvir with only two NS5 substitutions that have slight impact on viral fitness.
  • ||||||||||  Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. (Pubmed Central) -  Apr 19, 2026   
    Immunotherapy alone or with doublet chemotherapy is recommended for patients with mismatch repair deficient/microsatellite instability-high gastroesophageal cancer. Second-line therapy options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive gastric/GEJ adenocarcinoma, and immunotherapy for PD-L1 ?1 esophageal squamous cell carcinoma after first-line combination chemotherapy without immunotherapy.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
  • ||||||||||  Zontivity (vorapaxar) / Merck (MSD)
    Journal:  Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk. (Pubmed Central) -  Apr 19, 2026   
    Under venous shear in an endothelialized microfluidic system, GG platelets exhibited increased accumulation, which was reversed by PAR1 inhibition with vorapaxar...This study provides the first experimental evidence directly linking a highly prevalent human GRK5 variant to defective PAR1 regulation and increased thrombotic risk. Together, these findings establish that the GRK5 GG genotype confers increased thrombotic potential through impaired PAR1 desensitization, providing mechanistic insight that connects human genetics, thrombin receptor signaling, and thrombotic disease.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage-Nucleus Pulposus Cell Crosstalk. (Pubmed Central) -  Apr 19, 2026   
    DPP4 was a causal driver of IVDD, and its inhibition by sitagliptin mitigated degeneration by disrupting the pathogenic positive feedback loop between macrophages and NP cells. These findings reposition sitagliptin, a clinically approved antidiabetic drug, as a promising therapeutic candidate for IVDD, highlighting the translational potential of targeting DPP4 and its downstream inflammatory cascades.
  • ||||||||||  Journal, Adverse events, Real-world evidence:  Drug-induced interstitial lung disease: a real-world pharmacovigilance study based on an adverse event reporting system. (Pubmed Central) -  Apr 19, 2026   
    The data mining results indicate that fremanezumab resulted in the strongest AE signals of the four methods...The KEGG pathway enrichment analysis showed that the most possible mechanisms of rimegepant, atogepant, and ubrogepant induce RP is the PI3K signaling pathway. This study comprehensively displays all drugs related to DILD from a landscape perspective, promoting the rational use of drugs in clinical practice.
  • ||||||||||  Remicade (infliximab) / J&J, Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Checkpoint inhibition:  A Case of Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab. (Pubmed Central) -  Apr 19, 2026   
    This highlights the importance of early diagnosis of immune-related gastritis by endoscopic and histological findings. Prompt evaluation of steroid efficacy and the early use of infliximab in steroid refractory cases are emphasized for effective management of immune-related gastritis as the indications for immune checkpoint inhibitors have expanded.
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Journal:  An integrated analysis of lactylation signature reveals PRDX1 as a therapeutic target of keloid pathogenesis. (Pubmed Central) -  Apr 19, 2026   
    Regulatory network analysis predicted shared transcription factors (KLF12, NFKB1, MYC) governing hub genes, while drug screening prioritized three clinically actionable compounds (acetaminophen, valproic acid, vorinostat) targeting PRDX1. These findings establish lactylation as a critical regulator of keloid pathogenesis and identify PRDX1 as a promising therapeutic target.